



## Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

February 17, 2026

B-Body<sup>®</sup> platform complements Twist's antibody discovery offering enabling rapid, efficient and precise expression and discovery of complex bispecific antibody therapeutics

Platform to power high-throughput characterization of bispecific antibodies to fuel AI-enabled and traditional drug discovery

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 17, 2026-- [Twist Bioscience Corporation](#) (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with [Invenra Inc.](#) ("Invenra"), a company that has developed platform technologies to discover therapeutic antibody candidates. Under the terms of the agreement, Twist will become the co-exclusive provider, together with Invenra, of Invenra's B-Body<sup>®</sup> bispecific antibody platform ("B-Body platform"), extending Twist's antibody discovery services.

"Bispecific antibodies have emerged as one of the most promising therapeutic modalities, validated both clinically and commercially, with the ability to unlock new mechanisms of action. This is exemplified in that the development of this class of biological therapeutic is growing at an accelerated pace compared to more standard monospecific approaches," said Emily M. Leproust, CEO and co-founder of Twist Bioscience. "Licensing the B-Body platform gives us direct access to a proven and scalable bispecific antibody platform that complements our current service offerings and further solidifies our position at the forefront of enabling next-generation biologics discovery for our customers, whether through traditional methods or AI-enabled."

The B-Body platform expands and complements Twist's current antibody discovery services as well as giving customers the plug-and-play flexibility to utilize their own pre-existing monospecific antibodies in the B-Body platform. With a comprehensive offering spanning in vivo, in vitro and AI-enabled discovery methods combined with high throughput antibody expression and characterization capabilities, and now adding on a powerful bispecific technology, Twist meets customers' needs whether they are utilizing Twist's biologics discovery capabilities, using Twist as a wet lab partner or training a large language model (LLM).

"The B-Body platform is designed to overcome multiple challenges commonly faced by bispecifics by enabling extremely favorable and predictable developability characteristics as well as at high concentrations with low viscosity needed for subcutaneous delivery," said Roland Green, Ph.D., CEO and chairman of Invenra. "By licensing our B-Body technology to Twist, we leverage their expertise and infrastructure to enable broad access to the platform to support the rapidly growing demand for the development of next-generation bispecifics that address unmet medical needs for a breadth of diseases."

Twist will provide Invenra with an upfront payment of \$5 million in cash and \$15 million in Twist common stock. In a secondary transaction, Twist is taking an approximately 6% ownership position in Invenra through a preferred stock purchase from existing Invenra stockholders for \$13.8 million in Twist common stock. Twist receives all revenue generated for bispecific antibody discovery services conducted by Twist as well as all license revenue, whether signed by Invenra or Twist. Twist will pay Invenra a 20% royalty on all license revenue.

### Conference Call Information

The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today. The conference call will be webcast live through the Investor Relations section under the "Company" tab at [www.twistbioscience.com](http://www.twistbioscience.com). Those parties interested in participating via telephone must register on the Company's Investor Relations website or by clicking [here](#). Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks in the Investor Relations section at [www.twistbioscience.com](http://www.twistbioscience.com).

### About Twist Bioscience Corporation

At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts.

Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit [www.twistbioscience.com](http://www.twistbioscience.com).

Follow us on [LinkedIn](#) | [X](#) | [YouTube](#) | [Instagram](#) | [Bluesky](#)

### Twist Bioscience Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, statements regarding the ability to utilize the B-Body platform to expand service offerings and meet future demand for

bispecific therapeutics. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; the ability to integrate and leverage artificial intelligence and machine learning technologies to improve operational efficiency, product development, and customer solutions; the ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist's costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; the ability to maintain and enforce intellectual property protection; uncertainty as to economic and market conditions and the impact of adverse economic conditions; and the ability to obtain financing when necessary. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist's business in general, see Twist's risk factors set forth in Twist's Annual Report on Form 10-K for the year ended September 30, 2025 filed with the Securities and Exchange Commission (SEC) on November 17, 2025 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260217112800/en/): <https://www.businesswire.com/news/home/20260217112800/en/>

**For Investors:**

Angela Bitting  
SVP, Corporate Affairs  
925-202-6211  
[abitting@twistbioscience.com](mailto:abitting@twistbioscience.com)

**For Media:**

Amanda Houlihan  
Communications Manager  
774-265-5334  
[ahoulihan@twistbioscience.com](mailto:ahoulihan@twistbioscience.com)

Source: Twist Bioscience Corporation